| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A pocket companion to cell-free DNA (cfDNA) preanalytics
|
Bronkhorst, Abel J.
|
|
|
|
s1 |
p. S297-S308
|
artikel
|
| 2 |
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer
|
Muller, Mirte
|
|
|
|
s1 |
p. S327-S340
|
artikel
|
| 3 |
Book of Abstracts
|
Osredkar, Joško
|
|
|
|
s1 |
p. S1-S3
|
artikel
|
| 4 |
Circulating lung cancer biomarkers: From translational research to clinical practice
|
Qian, Xu
|
|
|
|
s1 |
p. S27-S33
|
artikel
|
| 5 |
Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction
|
Duffy, Michael J.
|
|
|
|
s1 |
p. S283-S295
|
artikel
|
| 6 |
Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer
|
Buma, Alessandra I.G.
|
|
|
|
s1 |
p. S207-S217
|
artikel
|
| 7 |
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
|
Moes-Sosnowska, Joanna
|
|
|
|
s1 |
p. S309-S325
|
artikel
|
| 8 |
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150
|
Mang, Anika
|
|
|
|
s1 |
p. S177-S190
|
artikel
|
| 9 |
Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer
|
van Delft, Frederik A.
|
|
|
|
s1 |
p. S269-S281
|
artikel
|
| 10 |
CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan
|
Muley, Thomas
|
|
|
|
s1 |
p. S163-S175
|
artikel
|
| 11 |
Factors influencing blood tumor marker concentrations in the absence of neoplasia
|
Trapé, Jaume
|
|
|
|
s1 |
p. S35-S63
|
artikel
|
| 12 |
Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations
|
Trulson, Inga
|
|
|
|
s1 |
p. S81-S98
|
artikel
|
| 13 |
Keynote Lectures’ Abstracts
|
Osredkar, Joško
|
|
|
|
s1 |
p. S5-S7
|
artikel
|
| 14 |
Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer
|
Rupp, Alexander
|
|
|
|
s1 |
p. S341-S353
|
artikel
|
| 15 |
Lung cancer biomarkers: Raising the clinical value of the classical and the new ones
|
Holdenrieder, Stefan
|
|
|
|
s1 |
p. S1-S7
|
artikel
|
| 16 |
Lung cancer tumor marker analysis: A clinical laboratory perspective
|
van Rossum, Huub H.
|
|
|
|
s1 |
p. S9-S14
|
artikel
|
| 17 |
Lung cancer tumor markers in serous effusions and other body fluids
|
Trapé, Jaume
|
|
|
|
s1 |
p. S99-S110
|
artikel
|
| 18 |
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – A CEPAC-TDM biomarker substudy
|
Geiger, Kimberly
|
|
|
|
s1 |
p. S355-S367
|
artikel
|
| 19 |
Oral Presentations’ Abstracts
|
Osredkar, Joško
|
|
|
|
s1 |
p. S9-S46
|
artikel
|
| 20 |
Poster Presentations’ Abstracts
|
Osredkar, Joško
|
|
|
|
s1 |
p. S47-S69
|
artikel
|
| 21 |
Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers
|
Canki, Esra
|
|
|
|
s1 |
p. S15-S25
|
artikel
|
| 22 |
Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update
|
Trulson, Inga
|
|
|
|
s1 |
p. S111-S161
|
artikel
|
| 23 |
Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission
|
Muley, Thomas
|
|
|
|
s1 |
p. S219-S232
|
artikel
|
| 24 |
Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy
|
Geiger, Kimberly
|
|
|
|
s1 |
p. S191-S206
|
artikel
|
| 25 |
Screening approaches for lung cancer by blood-based biomarkers: Challenges and opportunities
|
van den Broek, Daniel
|
|
|
|
s1 |
p. S65-S80
|
artikel
|
| 26 |
Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies
|
van den Heuvel, Michel
|
|
|
|
s1 |
p. S233-S268
|
artikel
|
Tijdschrift beschrijving